Endoscopic ultrasound-guided placement of fiducial markers for stereotactic body radiation therapy of pancreatic metastases from renal cell carcinoma

Isolated pancreatic metastases from renal cell carcinoma (RCC) have traditionally been treated with surgery or systemic therapy [1]. More recently, focal therapies such as endoscopic ultrasound (EUS)-guided radiofrequency ablation or stereotactic body radiation therapy (SBRT) have been reported in selected patients [2–4]. SBRT uses precision technology to accurately deliver high doses of radiation in a few treatment fractions to the tumor volume, while sparing the surrounding healthy tissues. Many SBRT protocols require the placement of fiducial markers in or near the tumor to facilitate accurate targeting [4,5]. Here we report EUS-guided fiducial placement for SBRT of pancreatic metastases in a 75-year-old woman with a history of left nephrectomy for RCC 20 years previously and a recent finding of two hypervascular pancreatic tumors on computed tomography (CT) scanning.

The procedure started with EUS examination of the entire pancreas, which revealed the two hypoechoic, well-delimited, well-vascularized tumors of 9 × 8 mm and 22 × 21 mm in size, in the pancreatic head and tail, respectively (▶ Video 1). Fine-needle biopsy (FNB) of the tumor in the tail was performed to confirm the diagnosis of RCC metastasis. Following FNB, a 0.018-inch platinum fiducial marker (LumiCoil; Boston Scientific) (▶ Fig. 1) was backloaded into a 22G needle (EZShot 3 plus; Olympus Europe) through the tip of the needle. After the tumor had been punctured and the needle tip positioned in its center under EUS guidance, the fiducial was deployed by pushing it out of the needle with the needle stylet. The same technique was used to deploy a second fiducial in the pancreatic head tumor (▶ Fig. 2). No adverse events were observed. Both fiducials were clearly visible and correctly positioned on imaging used for planning and the delivery of irradiation (▶ Fig. 3 and ▶ Fig. 4). On follow-up 1 year later, the pancreatic metastases were stable; however, pulmonary
metastases were detected, and systemic treatment was therefore started.

Endoscopy_UCTN_Code_TTT_1AS_2AD

Competing interests

M. Polkowski has received consultancy and speaker’s fees from Olympus. K. Pawlewicz, K. Skoczylas, E. Wronska, M. Lenarcik, and J. Regula declare that they have no conflict of interest.

The authors

Marcin Polkowski1,2, Konrad Pawlewicz3, Krzysztof Skoczylas1,2, Ewa Wróńska1,2, Małgorzata Lenarcik1,4, Jarosław Regula1,2

1 Department of Gastroenterology, Hepatology and Clinical Oncology, Center of Postgraduate Medical Education, Warsaw, Poland
2 Department of Oncological Gastroenterology, The Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
3 Department of Radiotherapy, The Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
4 Department of Pathology and Laboratory Medicine, The Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Corresponding author

Marcin Polkowski, MD, PhD
Department of Gastroenterology Hepatology and Clinical Oncology, Center of Postgraduate Medical Education, Roentgena 5, 02-781 Warsaw, Poland
mp.polkowski@gmail.com

References


Bibliography

Endoscopy 2023; 55: E876–E877
DOI 10.1055/a-2109-0300
ISSN 0013-726X © 2023. The Author(s).
This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Fig. 3 Computed tomography image used for radiotherapy planning showing the fiducial marker (encircled in green) implanted in the tumor of the pancreatic tail (encircled in red). Organs at risk (stomach, bowel) are marked in blue.

Fig. 4  Cone-beam computed tomography (CBCT) image showing the fiducial marker implanted in the tumor of the pancreatic tail (encircled in red). The tumor itself is not visible, because of the low soft tissue contrast resolution of CBCT imaging; the radiopaque marker is essential for target volume localization. CBCT is performed before delivery of each radiation fraction to verify the target position.